0001193125-24-168554.txt : 20240626 0001193125-24-168554.hdr.sgml : 20240626 20240626081529 ACCESSION NUMBER: 0001193125-24-168554 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240626 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240626 DATE AS OF CHANGE: 20240626 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vir Biotechnology, Inc. CENTRAL INDEX KEY: 0001706431 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 812730369 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39083 FILM NUMBER: 241070679 BUSINESS ADDRESS: STREET 1: 1800 OWENS STREET STREET 2: SUITE 900 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 415-906-4324 MAIL ADDRESS: STREET 1: 1800 OWENS STREET STREET 2: SUITE 900 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 8-K 1 d835539d8k.htm 8-K 8-K
false 0001706431 0001706431 2024-06-26 2024-06-26

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 26, 2024

 

 

Vir Biotechnology, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39083   81-2730369

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

1800 Owens Street, Suite 900

San Francisco, California 94158

(Address of principal executive offices, including zip code)

(415) 906-4324

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.0001 par value   VIR   Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 8.01

Other Events.

On June 26, 2024, Vir Biotechnology, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration (the “FDA”) has cleared its investigational new drug application and granted Fast Track designation for the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta infection (the “Fast Track Designation”). A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

Forward-Looking Statements

This disclosure, including the press release filed herewith as Exhibit 99.1, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “plan,” “potential,” “aim,” “expect,” “anticipate,” “promising” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Vir’s expectations and assumptions as of the date of this Current Report on Form 8-K. Forward-looking statements contained herein include, but are not limited to, statements regarding the Company’s strategy and plans, the potential clinical effects, benefits, safety and efficacy of tobevibart and elebsiran, the timing, nature and significance of data from the Company’s multiple ongoing trials evaluating tobevibart and elebsiran, including the previously announced Phase 2 SOLSTICE data, the timing of any further releases of data or of any presentations or investor conference calls, the Company’s plans and expectations for its chronic hepatitis delta and chronic hepatitis B programs, the Company’s ability to realize the benefits from receiving the Fast Track Designation from the FDA, and risks and uncertainties associated with drug development and commercialization. Many factors may cause differences between current expectations and actual results, including that the Fast Track Designation might not result in a more expedited development or regulatory review process, and such a designation does not increase the likelihood that the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta infection will receive marketing approval in the United States; the Fast Track Designation does not change the standards for regulatory approval; the FDA may later decide that the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta infection no longer meets the conditions for qualification or that the time period for FDA review or approval will not be shortened; unexpected safety or efficacy data or results observed during clinical trials or in data readouts; the occurrence of adverse safety events; risks of unexpected costs, delays or other unexpected hurdles; difficulties in collaborating with other companies; successful development and/or commercialization of alternative product candidates by the Company’s competitors; changes in expected or existing competition; delays in or disruptions to the Company’s business or clinical trials due to geopolitical changes or other external factors; and unexpected litigation or other disputes. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements, or the scientific data presented. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements herein are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as required by law, the Company assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit
No.

   

Description

99.1    Press Release of the Company, dated June 26, 2024
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    VIR BIOTECHNOLOGY, INC.
Date: June 26, 2024     By:  

/s/ Marianne De Backer

      Marianne De Backer, M.Sc., Ph.D., MBA
            Chief Executive Officer
 EX-99.1 2 d835539dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection

Fast Track designation follows positive preliminary Phase 2 trial data presented at the European Association for the Study of the Liver Congress 2024 and underscores the unmet need for people living with chronic hepatitis delta

SAN FRANCISCO, June 26, 2024 – Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application and granted Fast Track designation for the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta infection. Tobevibart, an investigational monoclonal antibody, and elebsiran, an investigational small interfering ribonucleic acid, are currently being evaluated in the Company’s Phase 2 SOLSTICE hepatitis delta clinical trial, with complete 24-week treatment data on track to be reported in the fourth quarter.

“The IND clearance and Fast Track designation from the FDA, along with the encouraging preliminary data from our Phase 2 hepatitis delta trial, underscore the potential of tobevibart and elebsiran to transform the treatment landscape for people living with this severe and life-threatening disease,” said Marianne De Backer, M.Sc., Ph.D., MBA, Vir’s Chief Executive Officer. “We are committed to working closely with health authorities to bring this potential groundbreaking treatment to patients as quickly as possible, addressing a critical unmet medical need.”

The FDA’s Fast Track designation is intended to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The World Health Organization considers hepatitis delta to be the most severe form of chronic viral hepatitis due to more rapid progression towards liver cancer and liver-related death. It is estimated that at least 12 million people are living with chronic hepatitis delta globally.

In June, the Company announced preliminary Phase 2 SOLSTICE trial data which suggests treatment with tobevibart alone or in combination with elebsiran was generally well tolerated and participants achieved high rates of virologic response at weeks 12 and 24, durable virologic response through 48 weeks, and high rates of ALT normalization. The complete 24-week treatment data is expected in the fourth quarter. The Company is working to expedite the initiation of its next study, the ECLIPSE trial. The open-label, randomized, controlled ECLIPSE trial is designed to support potential registration and will evaluate the safety and efficacy of a monthly-administered subcutaneous injection of tobevibart and elebsiran using the current standard of care therapy as a comparator.

About the Phase 2 SOLSTICE Trial

The SOLSTICE trial (NCT05461170) is evaluating the safety, tolerability and efficacy of tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta. One cohort is evaluating the combination of tobevibart and elebsiran dosed every 4 weeks with a second cohort evaluating tobevibart monotherapy every 2 weeks. Approximately 50% of participants have compensated cirrhosis.

About Tobevibart (VIR-3434)

Tobevibart is an investigational subcutaneously administered antibody designed to inhibit entry of hepatitis B and hepatitis delta viruses into hepatocytes, neutralize both hepatitis B virus and hepatitis delta virus virions, and to reduce the level of virions and subviral particles in the blood. Tobevibart, which incorporates Xencor’s Xtend™ and other Fc technologies, has been engineered to have an extended half-life and was identified using Vir’s proprietary monoclonal antibody discovery platform.

About Elebsiran (VIR-2218)

Elebsiran is an investigational subcutaneously administered hepatitis B virus-targeting small interfering ribonucleic acid (siRNA) designed to degrade hepatitis B virus RNA transcripts and limit the production of hepatitis B surface antigen. Vir believes it has the potential to have direct antiviral activity against hepatitis B virus and hepatitis delta virus. It is the first siRNA in the clinic to include Enhanced Stabilization Chemistry Plus (ESC+) technology to enhance stability and minimize off-target activity, which potentially could result in an increased therapeutic index. Elebsiran is the first asset in the Company’s collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical trials.

About Vir Biotechnology, Inc.

Vir Biotechnology, Inc. is an immunology company focused on powering the immune system to transform lives by treating and preventing infectious diseases and other serious conditions, including viral-associated diseases. Vir has assembled two technology platforms that are designed to modulate the immune system by exploiting critical observations of natural immune processes. Its current clinical development pipeline consists of product candidates targeting hepatitis delta and hepatitis B viruses, and human immunodeficiency virus. Vir has several preclinical candidates in its pipeline, including those targeting influenza A and B, COVID-19, RSV/MPV and HPV. Vir routinely posts information that may be important to investors on its website.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “plan,” “potential,” “aim,” “expect,” “anticipate,” “promising” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Vir’s expectations and assumptions as of the date of this press release. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Vir’s strategy and plans, the potential clinical effects of tobevibart and elebsiran, the potential benefits, safety and efficacy of tobevibart and elebsiran, data from Vir’s multiple ongoing trials evaluating tobevibart and elebsiran, the ability of tobevibart and elebsiran (as monotherapies or combination therapies) to treat and/or prevent chronic hepatitis Delta (CHD) or chronic hepatitis B virus (CHB), Vir’s plans and expectations for its CHD and CHB programs, the timing and outcome of Vir’s planned interactions with the FDA, Vir’s ability to realize the benefits from receiving the Fast Track designation from the FDA, whether Vir maintains Fast Track designation and/or receives any additional accelerated development paths from the FDA for tobevibart and elebsiran (as monotherapies or combination therapies) to treat and/or prevent CHD or CHB, timing and enrollment for Vir’s ECLIPSE trial, and risks and uncertainties associated with drug development and commercialization. Many factors may cause differences between current expectations and actual results, including that receiving Fast Track

 

2

designation might not result in a more expedited development or regulatory review process, and such a designation does not increase the likelihood that the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta infection will receive marketing approval in the United States; the Fast Track designation does not change the standards for regulatory approval; the FDA may later decide that the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta infection no longer meets the conditions for qualification or that the time period for FDA review or approval will not be shortened; unexpected safety or efficacy data or results observed during clinical trials or in data readouts; the occurrence of adverse safety events; risks of unexpected costs, delays or other unexpected hurdles; difficulties in collaborating with other companies; successful development and/or commercialization of alternative product candidates by Vir’s competitors; changes in expected or existing competition; delays in or disruptions to Vir’s business or clinical trials due to geopolitical changes or other external factors; and unexpected litigation or other disputes. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements, or the scientific data presented. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Vir’s filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as required by law, Vir assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Contacts:

Media

Carly Scaduto

Senior Director, External Communications

cscaduto@vir.bio

+1 314-368-5189

Investors

Richard Lepke

Senior Director, Investor Relations

rlepke@vir.bio

+1 978-973-9986

 

3

EX-101.SCH 3 vir-20240626.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 vir-20240626_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 vir-20240626_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g835539g0626060813808.jpg GRAPHIC begin 644 g835539g0626060813808.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document and Entity Information
Jun. 26, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001706431
Document Type 8-K
Document Period End Date Jun. 26, 2024
Entity Registrant Name Vir Biotechnology, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-39083
Entity Tax Identification Number 81-2730369
Entity Address, Address Line One 1800 Owens Street
Entity Address, Address Line Two Suite 900
Entity Address, City or Town San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94158
City Area Code (415)
Local Phone Number 906-4324
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.0001 par value
Trading Symbol VIR
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.vir.bio//20240626/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d835539d8k.htm vir-20240626.xsd vir-20240626_lab.xml vir-20240626_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d835539d8k.htm": { "nsprefix": "vir", "nsuri": "http://www.vir.bio/20240626", "dts": { "inline": { "local": [ "d835539d8k.htm" ] }, "schema": { "local": [ "vir-20240626.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "vir-20240626_lab.xml" ] }, "presentationLink": { "local": [ "vir-20240626_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://www.vir.bio//20240626/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-06-26_to_2024-06-26", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d835539d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-06-26_to_2024-06-26", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d835539d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.vir.bio//20240626/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.vir.bio//20240626/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.vir.bio//20240626/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.vir.bio//20240626/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.vir.bio//20240626/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.vir.bio//20240626/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.vir.bio//20240626/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.vir.bio//20240626/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.vir.bio//20240626/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.vir.bio//20240626/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.vir.bio//20240626/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.vir.bio//20240626/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.vir.bio//20240626/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.vir.bio//20240626/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.vir.bio//20240626/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.vir.bio//20240626/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.vir.bio//20240626/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.vir.bio//20240626/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.vir.bio//20240626/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.vir.bio//20240626/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.vir.bio//20240626/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.vir.bio//20240626/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.vir.bio//20240626/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001193125-24-168554-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-168554-xbrl.zip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end XML 18 d835539d8k_htm.xml IDEA: XBRL DOCUMENT 0001706431 2024-06-26 2024-06-26 false 0001706431 8-K 2024-06-26 Vir Biotechnology, Inc. DE 001-39083 81-2730369 1800 Owens Street Suite 900 San Francisco CA 94158 (415) 906-4324 false false false false Common Stock, $0.0001 par value VIR NASDAQ false